Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer

Dotan Efrat; Cohen Steven J.; Starodub Alexander N.; Lieu Christopher H.; Messersmith Wells A.; Simpson Pamela S.; Guarino Michael J.; Marshall John L.; Goldberg Richard M.; Hecht J. Randolph; Wegener William A.; Sharkey Robert M.; Govindan Serengulam V.; Goldenberg David M.; Berlin Jordan D.

首页> 外文期刊>Journal of Clinical Oncology >Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer

【24h】

Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer

机译：耐火或复发转移性结直肠癌患者的Labetuzuamab Govitecan（抗CeAcam5 / Sn-38抗体 - 药物缀合物）的I / II试验

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2017年第29期|共12页
作者
Dotan Efrat; Cohen Steven J.; Starodub Alexander N.; Lieu Christopher H.; Messersmith Wells A.; Simpson Pamela S.; Guarino Michael J.; Marshall John L.; Goldberg Richard M.; Hecht J. Randolph; Wegener William A.; Sharkey Robert M.; Govindan Serengulam V.; Goldenberg David M.; Berlin Jordan D.;
展开▼
作者单位

Fox Chase Canc Ctr 333 Cottman Ave Philadelphia PA 19111 USA;

Fox Chase Canc Ctr 333 Cottman Ave Philadelphia PA 19111 USA;

Indiana Univ Hlth Ctr Canc Care Goshen IN USA;

Univ Colorado Ctr Canc Aurora CO USA;

Univ Colorado Ctr Canc Aurora CO USA;

Helen F Graham Canc Ctr &

Res Inst Newark DE USA;

Helen F Graham Canc Ctr &

Res Inst Newark DE USA;

Georgetown Univ Hosp Ruesch Ctr Cure GI Canc Washington DC 20007 USA;

Ohio State Univ Ctr Comprehens Canc Columbus OH 43210 USA;

Univ Calif Los Angeles Jonsson Comprehens Canc Ctr Los Angeles CA 90024 USA;

Immunomedics Morris Plains NJ USA;

Immunomedics Morris Plains NJ USA;

Immunomedics Morris Plains NJ USA;

Immunomedics Morris Plains NJ USA;

Vanderbilt Ingram Canc Ctr Nashville TN USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer [J] . Dotan Efrat, Cohen Steven J., Starodub Alexander N., Journal of Clinical Oncology . 2017,第29期

机译：耐火或复发转移性结直肠癌患者的Labetuzuamab Govitecan（抗CeAcam5 / Sn-38抗体 - 药物缀合物）的I / II试验
2. Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients [J] . European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2017,第期

机译：用伊立替康/西替昔单抗的治疗序列，然后进行Folfox-4或转移性结肠直肠癌患者的反向策略，在第一线Folfiri / Bevacizumab后进展：用于研究胃肠癌期III的意大利组，随机试验比较两种治疗序列结肠直肠转移性患者
3. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. [J] . Van-Cutsem E, Peeters M, Siena S, Journal of Clinical Oncology . 2007,第13期

机译：在化疗难治性转移性结直肠癌患者中，帕尼单抗联合最佳支持治疗与单独最佳支持治疗的开放标签III期试验。
4. Effects of laser immunotherapy on late-stage, metastatic breast cancer patients in a Phase Ⅱ clinical trial [C] . Gabriela L. Ferrel, Feifan Zhou, Xiaosong Li, Biophotonics and immune responses IX . 2014

机译：Ⅱ期临床试验中激光免疫疗法对晚期转移性乳腺癌患者的影响
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. A phase II study of NK012 a polymeric micelle formulation of SN-38 in unresectable metastatic or recurrent colorectal cancer patients [O] . Tetsuya Hamaguchi, Akihito Tsuji, Kensei Yamaguchi, -1

机译：NK012是SN-38的聚合物胶束制剂的II期研究用于不可切除转移或复发的结直肠癌患者
7. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial [O] . A. Bardia, W.A. Messersmith, E.A. Kio, 2021

机译：Sacituzumab Govitecan，针对上皮癌患者的Trop-2定向抗体 - 药物缀合物：最终安全性和疗效结果来自I / II IMMU-132-01篮子试验

Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer

摘要

著录项

相似文献

相关主题

期刊订阅